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Abstract Several epidemiological studies have shown a positive association between adult height and cancer inci-dence. 
The only study conducted among women on mouth and pharynx cancer risk, however, reported an inverse association. 
This study aims to investigate the association between height and the risk of head and neck cancer (HNC) within a large 
international consortium of HNC. We ana-lyzed pooled individual-level data from 24 case–control studies participating in the 
International Head and Neck Cancer Epidemiology Consortium. Odds ratios (ORs) and 95 % confidence intervals (CIs) 
were estimated separately for men and women for associations between height and HNC risk. Educational level, 
tobacco smoking, and alcohol consumption were included in all regression models. Stratified analyses by HNC subsites 
were performed. This project included 17,666 cases and 28,198 controls. We found an inverse association between 
height and HNC (adjusted OR per 10 cm height = 0.91, 95 % CI 0.86–0.95 for men; adjusted OR = 0.86, 95 % CI 0.79–
0.93 for women). In men, the estimated OR did vary by educational level, smoking status, geographic area, and control 
source. No differences by subsites were detected. Adult height is inversely associated with HNC risk. As height can be 
considered a marker of childhood illness and low energy intake, the inverse association is consistent with prior studies 
showing that HNC occur more frequently among deprived individuals. Further studies designed to elucidate the 
mechanism of such association would be warranted. 
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Background 
 
Head and neck cancer (HNC) is the sixth most common cancer worldwide, with more than half a million cases and 300,000 deaths in 
2008 [1]. These malignancies, the majority of which are squamous cell carcinomas, include cancers of the oral cavity, oropharynx, 
hypopharynx and larynx. Tobacco smoking and alcohol consumption are predominant risk fac-tors for HNC, although other 
factors, including passive smoking [2, 3], human papillomavirus (HPV) infection [4], low body-mass index [5], low levels of 
recreational physical activity [6], poor dietary pattern [7], low socioeconomic status [8] and family history of cancer [9], affect 
the risk.  
Increasing cancer risk with increasing adult height has been reported for all cancers combined [10–12], and for several specific 
cancer sites, such as breast, ovary, prostate, colon, rectum, testis, malignant melanoma, endometrium, kidney, non-Hodgkin 
lymphoma and leukaemia [13, 14, 16–20]. The World Cancer Research Fund reported in 2007 that evidence of an increasing risk 
associated with attained adult height was convincing for colorectal and postmenopausal breast cancer, while it was probable for 
pancreatic, ovarian, and premeno-pausal breast cancer. Evidence was limited, however, for endometrial cancer [21]. A positive 
association has also been reported between adult height and cancer mortality [15, 22, 23]. On the other hand, an inverse relation was 
reported for stomach and oesophagus cancer in some studies [10, 24–27], and recently also for mouth and pharynx cancer. Based on 
1,095 incident cases of mouth and pharynx cancers within the Million Women cohort Study [11], a risk reduction of 6 % per 10 cm 
increasing adult height was reported. Additionally, the Emerging Risk Factors Collaboration reported a reduction of 13 % per 6.5 cm 
increasing adult height for oral cancer mortality (95 % CI 5–21 %), based on a pooled analysis of 632 cancer deaths from a large 
number of cohort studies [23].  
In general, a person’s maximum height is determined by a combination of genetic factors and environmental expo-
sures both in utero and during childhood and adolescence, so that height can be considered as a biomarker of the 
interplay of genetic endowment and early-life experiences [28, 29]. The extent to which a person can reach his/her 
genetically determined height is therefore strongly influ-enced by living conditions and the family’s and previous 
generations’ socioeconomic status (SES) [30]. Besides SES, insulin-like growth factor I (IGFI) circulating levels are 
also strongly related with childhood and adolescence skeletal growth [31], with IGFI being positively associated with 
cancer risk [32].  
The purposes of this study are to examine the association between height and the risk of HNC in a pooled analysis of case–
control studies participating in the International Head and Neck Cancer Epidemiology (INHANCE) Consortium, and to test 
this association in HNC subsites. 
 
 
Materials and methods 
 
Studies and participants 
 
We conducted the pooled analysis by using data from independent case–control studies participating in the IN-HANCE 
Consortium. The INHANCE Consortium was established in 2004 and includes 35 head and neck cancer case–control 
studies (several of which are multicenter) on 25,478 cases and 37,111 controls (data version 1.5) [33]. Cases included 
patients with invasive tumors of the oral cavity, oropharynx, hypopharynx, larynx, oral cavity or pharynx not otherwise 
specified or overlapping, as defined previously [34].  
Details of the case–control studies and data pooling methods for the INHANCE Consortium have been previ-ously 
described [34]. Face-to-face interviews are con-ducted in all studies by trained personnel, except for the following 
studies: Boston, Germany-Saarland, MSKCC New York, and Japan (2001–2005), in which subjects completed self-
administered questionnaires. All the studies were performed according to the Declaration of Helsinki and were 
approved by the local ethics committees. Written informed consents were obtained from all study subjects. 
 
Inclusion criteria 
 
Studies in the INHANCE Consortium were eligible for inclusion in the current analysis only if information on height 
was available for at least 80 % of the subjects. Additionally, among the eligible studies, subjects were excluded if they 
were: aged \18; \20 cm in height; had missing information on age, gender or height; or had missing information on the 
site of origin of cancer. 
Study variables 
 
Variables were formatted to be consistently classified across studies into standard categories, including age (\50, 50–59, 
60–69, C70 years), body-mass index [\18.5 (underweight), 18.5–24.9 (normal weight), 25–29.9 (over-weight), C30 
(obese) kg/m2], education level (no formal education, less than junior high school, some high school, high-school 
graduate, vocational/some college, or college graduate/postgraduate), cigarette smoking status (never, former, current), 
years of smoking (\10, 10–19, 20–29, 30–39, C40), number of cigarettes smoked per day (\10, 10–19, 20–29, 30–39, 
C40), alcohol drinking status (never, former, current), alcohol consumption as number of drinks consumed per day (\1, 
1–2, 3–4, C5), geographic area (Europe, North America, Central and South America, and Asia), source of control 
subjects (hospital-based versus population-based), cancer subsite (oral cavity, oropharynx, hypopharynx, and larynx) 
[34].  
Body mass index was calculated as the weight divided by the height squared (weight (kg)/height (m)2) and cate-
gorized into four groups according to World Health Organization criteria as previously reported [35]. Subjects, who 
have not attained a high school graduation, were classified as having low education in the data analysis. A detailed 
description on the method used for data pooling on smoking and alcohol across different studies is provided in a 
previous paper [34].  
Height and weight were self-reported at the time of interview in all studies. All pooled data were cleaned and 
checked for internal consistency, and clarifications were requested from the original investigators when needed. 
 
 
Statistical analysis 
 
Descriptive analyses were conducted to describe the study population by demographic and known HNC risk factors. 
Height was expressed as quartiles of the distribution for the combined control group of all studies and for each gender 
respectively (\168, 168–172, 173–178, [178 cm for men; \157, 157–160, 161–165, [165 cm for women).  
The associations between HNC risk and height (per 10 cm increase) were assessed by estimating odds ratios (ORs) and 
95 % confidence intervals (CIs), using uncon-ditional logistic regression for each case–control study, adjusted by 
education level, cigarette smoking status, years of smoking, number of cigarettes smoked per day, and alcohol 
consumption as number of drinks consumed per day. The pooled effect estimates from all studies were estimated with 
random effect models and presented in a Forest plot. We quantified inconsistencies across studies and their impact on 
the analysis by using Cochrane’s Q and the I2 statistic [36, 37]. An estimate of the between-study variance was also 
computed using s2 statistic [38].  
To assess the impact of other potentially confounding factors, we examined the percent change in the age-adjusted 
pooled OR with the addition of each factor. Subgroup analyses were also conducted by geographic area, source of 
control subjects, cancer subsite, and selec-ted characteristics at recruitment: age, body-mass index, education level, 
smoking status, and alcohol drinking sta-tus. Statistical analyses were performed separately for men and women and 
were done with Stata software, version 12 (StataCorp. 2011. College Station, TX: StataCorp LP). All statistical tests 
were two-sided, and p values \ alpha (0.05) were considered statistically significant. 
 
 
Results 
 
Overall, of the 35 studies participating in the INHANCE Consortium (version 1.5 with 25,478 cases and 37,111 
controls), 11 were immediately excluded, as 6 did not have data on height [Baltimore, Beijing, France multicenter 
(1989–1991), Germany-Heidelberg, HOTSPOT, and Houston], and 5 did not provide data on height at the time of the 
analysis [Buffalo, Iowa, France (1987–1992), Rome, and Sao Paulo]. Furthermore, two centers (Goiania, Sao Paulo) 
from the Latin America multicenter study, and six centers (Australia, Aviano, Cuba, Milan, Sudan, Udine) from the 
International multicenter study were excluded. Figure 1 shows the selection process and lists the excluded case-control 
studies with reasons for their exclusion.  
Of the 24 case–control studies, we also excluded par-ticipants with missing data on height, age, and gender (1,148 cases 
and 581 controls). The final analysis included 17,666 cases and 28,198 controls. Among the cases, 4,714 were oral 
cancer, 6,254 were pharyngeal cancer (4,663 oropharynx and 1,591 hypopharynx), 1,970 were cancers of the oral cavity 
or pharynx not otherwise specified, 4,407 were laryngeal cancer and 321 overlapping. Details of the case–control 
studies are provided in Table 1. Nine studies were conducted in Europe, ten in North America, two in Central and South 
America, two in Asia, one study was conducted on four continents and coordinated by the International Agency for 
Research on Cancer (IARC). 
 
Table 2 reports the characteristics of the study popula-tion, which included 34,072 men (74.3 % of the entire 
population; 13,792 cases and 20,280 controls), and 11,792 women (25.7 %; 3,874 cases and 7,918 controls). Among 
these participants, both men and women, cases were more likely than controls to be underweight or normal weight, 
cigarette smokers, and alcohol drinkers. Controls had higher education levels than cases (Table 2).  
Table 3 shows the distribution of age and selected risk factors in control subjects according to gender-specific height 
quartiles. Both in men and women, the taller group tended to be younger, to have a higher level of education, and more 
likely to be current drinkers. Among men, taller individuals were less likely to be current smokers, while the reverse 
was true among women (Table 3).  
The adjusted ORs for HNC risk per 10 cm increase in height for the 24 studies are shown in Fig. 2. Among men, the 
pooled OR for height was 0.91 (95 % CI 0.86–0.95). There was little heterogeneity between the effect sizes, accounting 
for 18 % of the variation in point estimates by using the statistic I2. The estimate of the heterogeneity variance was 
0.002. The point estimate of the pooled ORs was less than 1.0 for 18 of the 24 studies (sign test, p \ 0.05).  
Among women, the pooled OR was 0.86 (95 % CI 0.79–0.93), and there was no evidence of heterogeneity across 
studies. The point estimate of the pooled ORs was less than 1.0 for 19 of the 24 studies (sign test, p \ 0.05).  
Figure 3 shows the ORs for HNC per 10 cm increase in height, in subgroups defined by geographic area, control 
source (hospital-based or population-based), cancer sub-site, and selected characteristics at recruitment. In men, the 
adjusted  ORs  varied by  education  level  (I2 = 62.7 %; s2 = 0.004), smoking status (I2 = 68.2 %; s2 = 0.003), 
geographic area (I2 = 63.3 %; s2 = 0.003), and control source (I2 = 87.7 %; s2 = 0.006). The OR was 0.87 (95 % CI 
0.82–0.91) for hospital-based case–control studies and 0.97 (95 % CI 0.91–1.03) for population-based case–con-trol 
studies. There was little association between height and HNC risk among men with at least high-school education, and 
in American populations. There was no substantial heterogeneity in the estimated association with height across strata 
of the variables among women (Fig. 3).  
We also examined whether estimates varied by gender. We found that pooled ORs and ORs in each group con-
sidered were consistent and did not differ by gender for the association between increasing height and HNC risk (data 
not shown). 
 
 
Discussion 
 
In this pooled analysis of 24 case–control studies including 13,792 men and 3,874 women with HNC, we found an 
inverse association between height and HNC risk. The estimated association was stronger in women than in men (14 vs. 
9 % risk reduction for per 10 cm increase in adult height). Furthermore, the estimated associations were rea-sonably 
homogeneous across studies. Our results are con-sistent with those from the only previous investigation on mouth and 
pharynx cancers from a large prospective female cohort study in UK, which reported a relative risk of 0.94 (95 % CI 
0.82–1.08) per 10 cm increase in height [11]. Additionally, the Emerging Risk Factors Collabora-tion recently reported 
an inverse association between adult height and oral cancer mortality, based on a large set of pooled cohort studies [23]. 
In our study, the inverse asso-ciation between height and HNC risk was minimal among American men, and it was 
weaker in population-based studies than in hospital-based studies among men (adjusted OR = 0.97 vs. 0.87).  
Within ethnic groups within countries, studies have shown that short stature is associated with poor health status [27]. It 
is known that people with high SES tend to be taller than those in lower socioeconomic classes [39, 40]. The key role of 
environmental factors in determining adult height is also evident when considering that mean adult height in 
industrialized countries markedly increased during the 20th century [41]. Therefore, since height can be considered as a 
marker of early life illness, nutrition and psychosocial stress [42], it is not surprising that several studies reported an 
inverse association between adult height and cardiovascular and respiratory disease risk [26, 43, 44]. The relationship 
between height and cancer, however, is conflicting. Some cohort studies conducted in different ethnic groups [10–12, 
14], reported a positive association between height and overall cancer incidence. However, for the mouth and pharynx 
[11] as well as stomach and esophagus, inverse associations were found [10, 24–27].  
The results of our pooled analysis suggests that taller people might be at a lower risk for HNC and corroborates the 
knowledge that HNC is more common among socio-economically deprived people [8, 45]. We cannot exclude the 
possibility that the observed inverse association between height and HNC risk is attributable to the unmeasured 
confounders of childhood or adolescent nutrition status, which are expected to influence both adult height and cancer 
risk. Childhood growth is indeed asso-ciated with parental SES [46, 47], and our pooled estimates are adjusted by adult 
education status, which is again a good proxy of parental education/SES [48]. However, we cannot rule out 
confounding by childhood nutrition.  
In this study the association between height and HNC risk differed by educational level, especially among men. 
Those with at least a high school degree are no longer at an increased risk, which suggests a possible residual con-
founding due to other unknown variables related to SES being the underlying factors of the height-HNC association in 
the overall analysis.  
In a Scottish study [26], authors postulated that the inverse association between stature and stomach cancer was due 
to Helicobacter pylori, which is associated with suboptimal childhood growth and is a causal component for gastric 
cancer [49, 50]. Additionally, the contribution of the infective component causes of HPV [4] in HNC etiol-ogy is not 
supposed to influence directly childhood and/or adolescent growth, so that we exclude a priori the potential for 
confounding or effect modification by HPV. 
 
In our analysis, the population-based studies among men did not show an inverse association of height with HNC risk, 
indicating the possible presence of selection bias with hospital controls. On the other hand, this modifying effect of control 
source was not evident among women. When stratifying on geographic region among men, an effect modification was found. 
American studies did not show an inverse association between stature and HNC risk. Both scenarios might be due to selection 
bias by education level, as hospital based studies have lower educational level among men in our pooled analysis (data not 
shown), while in North America we observed a higher education level of participants compared with the other regions (data 
not shown). Even though the stratified analyses are adjusted by educational level, some residual confounding might persist.  
While the present study has its strengths, including its very large size, its capacity to explore effect modification by 
several characteristics and the stratified analyses according to cancer subsites, it is not without limitations. Firstly, we 
did not have information on SES or education of the parents, and used the adult education of the subjects as a proxy, 
which might result in residual confounding. Sec-ondly, we did not have information on diet during child-hood and/or 
adolescence, which affects the growth thus might be key factor underlying the observed associations. Thirdly, we did 
not have information on trunk and leg length, which represent a more direct height component that some studies related 
with cancer outcomes [51]. Fourthly, we could not quantify the amount of information bias of self-reported height in 
our study, though we believe that its effect would be modest [52]. Fifthly, residual confounding by tobacco and alcohol 
cannot be excluded as these key risk factors for HNC might have been measured with error. Lastly, we could not assess 
the influence of birth cohort effect on the association between height and HNC, although we accounted for that by 
adjusting for age at diagnosis and showing the effect estimates in each study separately.  
In conclusion, in the present project of a large pool of case–control studies, taller men and women experienced a 
lower risk of HNC, controlling for potential confounding due to smoking, alcohol, and educational level. As it is 
thought that associations between height, birth weight, and cancer risk reflect some causal association with a combi-
nation of genetics, hormonal, nutritional, and other factors [21], we believe that the biological mechanisms underlying 
the association between height and HNC warrants further investigation.  
A Mendelian Randomization approach has been recently suggested to address the aforementioned research question 
[53]. By using the genes that regulate the height as a proxy of the effect of measured adult height in the association 
between height and cancer, we would expect to dissect the true effect of height on HNC, without confounding by 
environmental variables. 
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Table 1 Description of the 24 INHANCE case control studies included in the analysis of height and the risk of head and neck cancer  
Study Recruitment Case Control Participation rate (%) Frequency matched Matching Age Cases/ Site of tumour 
b   
location period source source (cases/controls) factors method eligibility Controls 
         Oral Pharynx Oral/ Larynx
         cavity  pharynx  
           NOS  
             
Europe             
Central 1998–2003 Hospital Hospital 96/97 Age, gender, ethnicity, Frequency C15 762/907 196 150 32 384
Europe   based  city        
France 2001–2007 Cancer Population 83/81 Age, gender, region Frequency 18–75 2,237/ 468 1,105 155 509
  registry based     3,555     
Germany, 2001–2003 Hospital Population 94/– Age, gender Frequency 50–75 94/94 15 43 9 27
Saarland   based          
Italy, Aviano 1987–1992 Hospital Hospital [95/95 – – [18 482/855 85 218 33 146
   based          
Italy, Milan 1984–1989 Hospital Hospital 95/95 – – \80 416/ 48 61 65 242
   based     1,531     
Italy, Milan 2006–2009 Hospital Hospital [95/[ 95 – – 18–80 368/755 85 38 18 227
   based          
Italy 1990–1996 Hospital Hospital [95/[ 95 – – 18–80 1,260/ 209 502 90 459
Multicenter   based     2,715     
Switzerland 1991–1997 Hospital Hospital [95/[ 95 – – \80 516/883 138 247 7 124
   based          
Western 2000–2005 Hospital Hospital 82/68 Age, gender, ethnicity, Frequency na 1,728/ 482 593 106 539
Europe   baseda  city   1,989     
North America             
Boston, MA 2003 Hospital Population 89/49 Age, gender, Frequency C18 584/659 139 291 43 111
   based  neighborhood        
Los Angeles, 1999–2004 Cancer Population 49/68 Age, gender, Individual 18–65 428/ 53 173 112 90
CA  registry based  neighborhood   1,038     
New York, 1992–1994 Hospital Hospital [95/[ 95 Age, gender Individual na 139/169 72 23 2 42
NY   based          
New York 1981–1990 Hospital Hospital 91/97 Age, gender, hospital, Frequency 21–80 1,118/ 536 518 64 0
Multicenter   based  year of interview   904     
North 1994–1997 Hospital Hospital 88/86 Age, gender Frequency [17 180/202 42 61 25 52
Carolina   based          
North 2002–2006 Cancer Population 82/61 Age, gender, ethnicity Frequency 20–80 1,368/ 194 442 251 481
Carolina  registry based     1,396     
Seattle, WA 1983–1987 Cancer Population 81/75 Age, gender Frequency 20–74 656/547 183 211 47 209
  registry based          
Seattle, WA 1992–1995 Cancer Population 63/61 Age, gender Frequency 18–65 284/477 157 116 11 0
  registry based          
Table 1 continued  
Study Recruitment Case Control Participation rate (%) Frequency matched Matching Age Cases/ Site of tumour 
b   
location period source source (cases/controls) factors method eligibility Controls 
         Oral Pharynx Oral/ Larynx
         cavity  pharynx  
           NOS  
              
Tampa, FL 1994–2000 Hospital Hospital 98/90 Age, gender, ethnicity Frequency C18 208/898 22 58 65 63 
   based           
US 1983–1984 Cancer Population 75/76 Age, gender, ethnicity  18–79 1,114/ 386 510 218 0 
Multicenter  registry based     1,268      
Central and South America            
South 2000–2003 Hospital Hospital 95/86 Age, gender, ethnicity, Frequency 15–79 1,295/ 279 267 81 612 
America   based  city   1,029      
Puerto Rico 1992–1995 Cancer Population 71/83 Age, gender Frequency 21–79 351/520 94 200 57 0 
  registry based           
Asia             
Japan 1988–2000 Hospital Hospital 97/97 Age, gender, year of visit Individual 18–79 402/ 119 85 198 0 
   based     1,532      
Japan 2001–2005 Hospital Hospital 97/97 Age, gender Individual 20–79 526/ 116 154 166 90 
   based     3,102      
Multi-Regional             
IARC 1992–1997 Hospital Hospital 89/87 Age, gender, center – na 1,150/ 596 188 115 0 
Multicenter   based     1,173      
Total        17,666/ 4,714 6,254 1,970 4,407 
        28,198      
 
This table does not include subjects that do not meet the inclusion criteria  
na not available, NOS not otherwise specified 
a Population-based for UK centers  
b 321 overlapping head and neck cases were included: Western Europe, n = 8; Seattle WA (1), n = 6; South America, n = 56; IARC Multicenter, n = 251 
 
Table 2 Characteristics of the 17,666 head and neck cancer cases and 28,198 controls from the 24 case control studies reporting on height 
within INHANCE Consortium 
 
Characteristics Men     Women     
         
  Cases (n = 13,792) Controls (n = 20,280) Cases (n = 3,874)  Controls (n = 7,918) 
             
  n % n % n %  n % 
             
 Age (years)            
\50 2,501 18.1 4,092 20.2 719 18.6 1,827 23.1 
 50–59 4,896 35.5 6,481 32.0 1,150 29.7 2,236 28.2 
 60–69 4,431 32.1 6,556 32.3 1,224 31.6 2,314 29.2 
 C70 1,964 14.2 3,151 15.5 781 20.2 1,541 19.5 
 Body-mass index (kg/m2)            
\18.5 859 6.7 430 2.2 507 14.2 347 4.6 
 18.5–24.9 7,019 54.4 8,544 43.5 1,937 54.4 3,830 50.4 
 25.0–25.9 3,821 29.6 8,107 41.3 717 20.1 2,202 29.0 
 C30.0 1,194 9.3 2,541 12.9 400 11.2 1,223 16.1 
 Height (cm)            
\160 630 4.8 922 4.6 1,582 43.0 3,137 40.5 
 160–169 3,865 29.2 5,971 30.0 1,662 45.2 3,676 47.4 
 170–179 6,330 47.8 9,567 48.1 419 11.4 897 11.6 
 180–189 2,229 16.8 3,132 15.7 11 0.3 37 0.5 
 C190 175 1.3 295 1.5 3 0.1 1 0.0 
 Educational level            
 No education 338 2.5 545 2.7 329 8.6 389 4.9 
 B Junior high school 4,919 36.4 6,280 31.2 972 25.4 2,542 32.2 
 Some high school 3,071 22.7 3,924 19.5 808 21.1 1,292 16.4 
 High school graduate 1,761 13.0 2,223 11.0 577 15.0 936 11.9 
 Technical school, some college 1,997 14.8 3,668 18.2 773 20.2 1,558 19.8 
[ College graduate 1,421 10.5 3,513 17.4 375 9.8 1,169 14.8 
 Cigarette smoking status            
 Never 1,142 8.3 5,841 28.9 1,294 33.5 5,100 64.6 
 Former 4,396 32.0 8,409 41.6 646 16.7 1,510 19.1 
 Current 8,213 59.7 5,980 29.6 1,926 49.8 1,290 16.3 
 Years of smoking            
 B10 405 3.2 1,572 11.0 108 4.2 496 17.8 
 11–20 778 6.2 2,487 17.4 186 7.3 572 20.6 
 21–30 2,299 18.3 3,407 23.8 489 19.1 702 25.2 
 31–40 4,347 34.7 3,664 25.6 898 35.1 597 21.5 
[40 4,703 37.5 3,159 22.1 875 34.2 416 14.9 
 Number of cigarettes per day            
 B10 1,383 11.3 3,389 25.3 541 21.4 1,209 44.4 
 11–20 5,142 41.9 5,811 43.3 1,025 40.5 1,019 37.4 
 21–30 2,549 20.8 1,987 14.8 488 19.3 256 9.4 
 31–40 2,116 17.3 1,394 10.4 347 13.7 163 6.0 
[40 1,073 8.7 834 6.2 132 5.2 76 2.8 
 Alcohol drinking status            
 Never 663 6.7 2,041 15.8 976 35.3 2,545 45.0 
 Former 2,384 24.0 2,006 15.6 524 19.0 590 10.4 
 Current 6,889 69.3 8,852 68.6 1,265 45.8 2,521 44.6 
 Drinks per day            
 Never 851 6.6 3,059 16.1 1,214 33.2 3,433 45.2 
             
 
 
 
 Table 2 continued               
                 
 Characteristics   Men       Women     
             
    Cases (n = 13,792) Controls (n = 20,280)  Cases (n = 3,874)  Controls (n = 7,918) 
                 
    n % n %   n %  n % 
             
\1 2,010 15.6 5,694 30.0  1,237 33.8 2,828 37.2 
 1–2 2,992 23.1 5,157 27.2  655 17.9 1,081 14.2 
 3–4 2,079 16.1 2,427 12.8  250 6.8 173 2.3 
 C5 4,993 38.6 2,623 13.8  306 8.4 77 1.0 
                
 Recruitment period: from 1981 to 2009             
 Total numbers of cases and controls vary because of missing data         
 Table 3 Distribution of age and selected risk factors by quartiles of height (cm), by gender, among INHANCE controls  
               
   Men      Women     
               
  \168  168–172 173–178 [178  \157  157–160 161–165 [165 
          
 Height (cm) 162.3 (4.1) 169.9 (1.4) 175.4 (1.8) 183.2 (3.8) 152.8 (3.9) 158.8 (1.3) 163.7 (1.3) 170.3 (3.4)
 Number of subjects 4,977  5,025 5,477 4,408  2,079 1,986 1,862 1,821 
 Age (years) 60.8 (10.1) 58.6 (10.5) 57.3 (10.9) 56.3 (11.1)  60.0 (12.0) 58.1 (12.1) 57.8 (12.1) 56.0 (12.6)
 Low educational level 50.9 % 41.2 % 26.2 % 16.6 %  48.2 % 39.5 % 33.4 % 26.2 % 
 Current cigarette smokers 33.9 % 29.8 % 28.6 % 25.4 %  12.3 % 15.8 % 17.7 % 20.0 % 
 Current alcohol drinkers 57.8 % 70.8 % 73.2 % 70.4 %  30.6 % 44.3 % 50.6 % 53.6 % 
 
Values are expressed as mean (standard deviation) or percentage 
 
 
 
